Stem Cell Therapy for Multiple Myeloma: Efficacy, Process, and Outcomes

Stem cell Therapy for Multiple myeloma is a hematopoietic stem cell transplantation, which is known as autologous stem cell transplantation. The therapy or transplantation removes abnormal plasma cells in the bone marrow that act as blood cancer in the patient’s body.

During the process, the patient’s stem cells, created by their own blood, are collected, stored, and returned after going through a high dose of chemotherapy. The treatment may not be a permanent cure; it is effective enough to extend the remission period before multiple myeloma relapses any time soon.

What is meant by Stem Cell Therapy in Multiple Myeloma?

In stem cell therapy, immature cells in the patient’s bone marrow are destroyed through rounds of high-dose chemotherapy, then replaced with a fresh batch of stem cells to restore blood production.

Chemotherapy is generally administered in order to remove or destroy malignant plasma cells, which critically harms a healthy bone marrow. Stem cell therapy serves as a rescue mechanism, depending on the transplant type, autologous or allogeneic; stem cells are infused into the patient’s bloodstream after chemotherapy, where they reach the bone marrow and begin producing new blood.

Why is a bone marrow transplant required for Multiple Myeloma?

As per the National Cancer Institute’s SEER program, the production of myeloma begins when white blood cells that are responsible for creating antibodies become abnormal. The abnormal cells are further assembled in the bone marrow and begin destroying the bone and organs like the kidneys.

The cancerous plasma cells in myeloma instantly stop blood production, forming monoclonal antibodies called M-protein. The symptoms of the condition are often remembered by an acronym referred to as CRAB, standing for Calcium elevation, Renal insufficiency, Anemia, and Bone lesions.

Explore the Types of Stem Cell Transplant for Multiple Myeloma

The following are some of the common forms of hematopoietic stem cell transplantation:

1. Autologous Bone Marrow Transplant: The treatment consists of collecting the patient’s own blood before performing a high dose of chemotherapy to eliminate the slightest risk of graft-versus-host disease as standard care in stem cell therapy for multiple myeloma.

2. Allogeneic Stem Cell Transplant: Utilizes stem cells from another person, likely to be an HLA-matched sibling or an unrelated donor. Less likely to be used for myeloma, as it involves a high risk of toxicity and GVHD. Generally used for chosen clinical trials or rare cases.

3. Tandem Transplant: Includes two autologous transplants with having the gaps of around 3-6 months between them for patients who failed to achieve even 50% success after the first treatment.

How Stem Cell Therapy for Multiple Myeloma Benefits Patients

The main advantage of stem cell therapy is its ability to deliver high doses of chemotherapy where it could critically damage the patient’s normal marrow.

Some of the potential advantages are the following:

• Intensely wipes out cancer cells to bring the patient’s body into remission.

• Ensures the cancer stays at a distance and helps patients to live longer without the condition growing any further.

• Instantly fixes the patient’s blood supply with healthy cells that were wiped out during chemo sessions.

• Manage to stall the illness, buying patients plenty of time before a relapse happens.

• Expands the life expectancy of patients ideal for the treatment.

Determine where to Avail Bone Marrow Transplant

The overall cost of stem cell therapy for multiple myeloma varies entirely on factors like country, preferred expert, hospital, type of care, and the level of complication.

Countries	Cost (USD)
India	$15,000 - $50,000+
The United States of America	$100,000 - $500,000+
The United Kingdom	$40,000 - $150,000+
Turkey	$32,000 - $55,000+
Middle East	$45,000 - $80,000+

Note that the figures mentioned above are approximate ranges and not guaranteed quotations.

Step-by-Step Process of Stem Cell Transplant

A thorough journey of stem cell therapy for multiple myeloma is generally divided into several phases, such as the following:

1. Thorough evaluation, including assessments like bone marrow, kidney, and heart evaluation, blood work, along with disease tests to determine a suitable transplant procedure.

2. Induction therapy consisting of 3-6 rounds of combined therapies to minimize the pressure of cancerous plasma cells in the body.

3. Mobilization of stem cells via medicines to stimulate the marrow to initiate blood formation in the bloodstream.

4. Stem cell collection, where apheresis separates blood from stem cells and is further collected for storage purposes.

5. Then takes place with conditioning therapy, with patients going through a high dose of chemotherapy to directly eliminate remaining myeloma and clear the bone marrow.

6. Infusion process where the stem cells are thawed and injected via the patient’s vein.

7. With engraftment and recovery, stem cells initiate the process of forming new blood cells.

8. Patients must avoid infection, illness, bleeding, mucositis, and other treatment-related complications.

9. Finally, comes maintenance therapy, requiring patients to opt for medications as experts suggest to extend disease control.

Also Read: Discover How Bone Marrow Donor Matching Process Works

Success Rate of Stem Cell Therapy for Multiple Myeloma

It should be remembered that stem cell therapy offers the possibility of prolonging remission among eligible patients. But there is no particular “Success rate” for the treatment.

Both outcomes and success rate vary depending on the patient’s age, treatment response, diagnosis, risk, therapy opted for, and genetics.

As per the study done by PubMed in 2024, patients with normal risk or multiple myeloma who went for an autologous stem cell procedure revealed a progression-free survival of 68.3 months of free survival. In addition, the progression-free survival of 5 years was approximately 55%, and overall survival was 83%.

Along with progression-free survival, the study also reported patients achieving a residual disease-negative response post-transplant in 64%.

Conclusion

While stem cell therapy for multiple myeloma offers extended remission, it also has considerable non-curative effects, as over time the clone cells can also lead to multiple myeloma relapse. According to the National Center for Biotechnology Information research index, early multiple myeloma relapse likely occurs within 18 to 24 months after transplant, putting approximately 15%-20% significantly at high risk.

To extend and improve the success rate of stem cell therapy for multiple myeloma, therapies like low-dose lenalidomide are suggested after engraftment, along with close consultation with a specialized oncologist or hematologist for a personalized treatment plan.